PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
0.38%
Some net income increase while AGEN is negative at -43.97%. John Neff would see a short-term edge over the struggling competitor.
3.11%
Some D&A expansion while AGEN is negative at -10.73%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-10.59%
Negative yoy deferred tax while AGEN stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-5.75%
Negative yoy SBC while AGEN is 53.28%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
224.19%
Slight usage while AGEN is negative at -178.01%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
351.62%
A yoy AP increase while AGEN is negative at -163.81%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-1034.42%
Negative yoy usage while AGEN is 119.64%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-5.75%
Negative yoy while AGEN is 219.70%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
10.47%
Some CFO growth while AGEN is negative at -28.81%. John Neff would note a short-term liquidity lead over the competitor.
90.96%
Some CapEx rise while AGEN is negative at -208.89%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
90.96%
Investing outflow well above AGEN's 35.78%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-1.15%
Both yoy lines negative, with AGEN at -100.00%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
-84.36%
Negative yoy issuance while AGEN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.